Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.
Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.
复制标题
索拉非尼对接受肝动脉化疗栓塞术的中度肝细胞癌患者的疗效和安全性的回顾性比较研究
DOI：
10.12998/wjcc.v6.i5.74
复制
发表时间：
2018-05-16
影响因子：
1.1
通讯作者：
Wang L
中科院分区：
文献类型：
--
作者：
Lei XF;Ke Y;Bao TH;Tang HR;Wu XS;Shi ZT;Lin J;Zhang ZX;Gu H;Wang L
目的评价索拉非尼联合肝动脉化疗栓塞术(TACE)治疗中期肝细胞癌的安全性和有效性。方法选择2009~2011年接受索拉非尼联合TACE或单纯TACE治疗的67例中期[巴塞罗那临床B期(BCLC-B)]肝癌患者为研究对象。随访至2014年，否则患者死亡。实验分为两组：试验组接受索拉非尼联合TACE治疗，对照组仅接受标准TACE治疗。结果Kaplan-Meier生存分析显示，试验组的中位总生存期为35.2mo，对照组为22.0mo(P<；0.05)。索拉非尼联合TACE治疗皮疹、手足综合征(HFS)和高血压的发生率高于单独TACE治疗(P<；0.05)。结论索拉非尼联合TACE治疗BCLC-B期肝癌较单纯TACE治疗明显延长患者的生存时间。索拉非尼最常见的不良反应是皮疹(31.6%)、HFS(39.5%)和高血压(31.6%)，但未见不可耐受的不良反应。COX多因素分析显示，BCLC-B级肝癌患者的生存取决于Child-Pugh分级、肿瘤直径以及索拉非尼联合TACE治疗与单纯TACE治疗相比。
AIM To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization (TACE) treatment for intermediate hepatocellular carcinoma (HCC). METHODS Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B (BCLC-B)] HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. Follow-up was until 2014 or patient death. Two groups were defined in the experiment: The experimental group, treated with sorafenib plus TACE, and the control group, treated with standard TACE alone. RESULTS The Kaplan-Meier survival analysis showed that the median overall survival (mOS) of the experimental group was 35.2 mo, while that of the control group was 22.0 mo (P < 0.05). Sorafenib plus TACE showed higher incidence rates of rash, hand-foot syndrome (HFS), and hypertension (P < 0.05) than TACE treatment alone. CONCLUSION Sorafenib plus TACE treatment for BCLC-B HCC significantly prolonged the mOS of patients compared to TACE treatment alone. The most common toxicities with sorafenib were rash (31.6%), HFS (39.5%) and hypertension (31.6%), but there were no intolerable adverse events. The Cox multivariate analysis showed that the survival of patients with BCLC-B HCC depended on the Child-Pugh classification, tumor diameter, and treatment with sorafenib plus TACE compared to TACE alone.
登录
查看更多内容
影响因子：
7.6
作者：
Cabrera R;Pannu DS;Caridi J;Firpi RJ;Soldevila-Pico C;Morelli G;Clark V;Suman A;George TJ Jr;Nelson DR
通讯作者：
Nelson DR
影响因子：
158.5
作者：
Llovet, Josep M.;Ricci, Sergio;Bruix, Jordi
通讯作者：
Bruix, Jordi
影响因子：
13.5
作者：
Lo, CM;Ngan, H;Wong, J
通讯作者：
Wong, J
索拉非尼对亚太地区晚期肝细胞癌患者的疗效和安全性：一项 III 期随机、双盲、安慰剂对照试验
影响因子：
51.1
作者：
Cheng, Ann-Lii;Kang, Yoon-Koo;Guan, Zhongzhen
通讯作者：
Guan, Zhongzhen
影响因子：
--
作者：
Cui, Han-zhi;Dai, Guang-hai;Chen, Li
通讯作者：
Chen, Li